Formycon AG
Formycon reports on the results of the Annual General Meeting

Press Release // June 13, 2024

Formycon reports on the results of the Annual General Meeting

• Management provides detailed report on financial year 2023 and current company performance
• Shareholders approve all agenda items and formally approve the acts of the members of the Management Board and Supervisory Board by large majority
• Supervisory Board becomes more international and expands to five members; Colin Bond, Dr Bodo Coldewey and Nicholas Haggar elected as new members of the Supervisory Board
• Supervisory Board elects Wolfgang Essler as new Chairman

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) held its Annual General Meeting on 12 June 2024 as an in-person event in Munich. In its presentation, the Management Board provided shareholders with a detailed report on the company’s development and answered all questions in the general debate. Dr Olaf Stiller, long-standing Chairman of the Supervisory Board, chaired the Annual General Meeting for the last time and was bid farewell with great appreciation for his successful collaboration.

The represented shareholders followed the proposals of the Management Board and Supervisory Board and approved all of the Executive Board’s proposed resolution resolutions with large majorities. Both the members of the Management Board and the Supervisory Board were given a formal approval of their actions with majorities of over 96 per cent in each case.

In order to reflect a more international focus and expanded industry and financial expertise on the Supervisory Board in future, new and independent members were elected to the Supervisory Board along with the decision to increase the size of the Supervisory Board from four to five members. Dr Bodo Coldewey, Managing Director of WEGA Invest GmbH, the Wendeln family office, and Nicholas Haggar, currently CEO of healthqube Ltd. and a long-standing executive at major pharmaceutical companies, were elected as new members of the Supervisory Board by large majorities. Dr Olaf Stiller and his deputy Peter Wendeln resigned from the Supervisory Board as planned with effect from the end of the Annual General Meeting. Colin Bond, currently still CFO of Sandoz Group AG, was also elected to the expanded Supervisory Board by a large majority with effect from 1 October 2024. The Supervisory Board was constituted immediately after the Annual General Meeting and elected Wolfgang Essler as the new Chairman and Nicholas Haggar as Deputy Chairman.

Wolfgang Essler, chief representative of the main shareholder ATHOS KG and new Chairman of the Supervisory Board of Formycon AG, commented: “I am very honoured to have been elected Chairman of the Supervisory Board and by the trust placed in me. I would first like to welcome Bodo, Colin and Nick as new members of the Supervisory Board of Formycon AG and look forward to continuing the good and constructive cooperation with my colleagues on the Supervisory Board and the Formycon Management Board. The global market for biosimilars will see strong growth in the coming years and Formycon is excellently positioned to play a decisive role in shaping this development. On behalf of the entire organisation, special thanks go to Dr Olaf Stiller and Peter Wendeln, who have been instrumental in shaping Formycon’s very successful development with great dedication and expertise in their many years as members of the Supervisory Board and in leading roles.”

Votes were cast for 62.16 percent of the share capital. The detailed voting results and further information on the 2024 Annual General Meeting can be found at Annual General Meeting – Formycon.

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Another five biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich and is listed on the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110

Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.